ProCE Banner Activity

Will Islatravir Add Value to Current ART Options?

Clinical Thought
Less frequent dosing may be a welcome theme among HIV drugs under investigation.

Released: October 10, 2019

Expiration: October 08, 2020

Share

Faculty

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Faculty Disclosure

Primary Author

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, and ViiV Healthcare.